Oncotarget · 2017 · 48 citations · 47 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyMelanoma PharmacotherapyTargeted Cancer TherapyTherapeutic ResistanceBraf V600 MutationsErk SignalingMapk SignalingMek InhibitionMek InhibitorsOncogenic Braf SignalingProtein Kinase InhibitorsTargeted Resistance Mechanisms
// Corinna Kosnopfel 1 , Tobias Sinnberg 1 , Birgit Sauer 1 , Heike Niessner 1 , Anja Schmitt 2 , Elena Makino 1 , Andrea Forschner 1 , Stephan Hailfinger 2 , Claus Garbe 1 , Birgit Schittek 1 1 Division of Dermatooncology, Department of Dermatology, University of Tübingen, Tübingen, Germany 2 Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany Correspondence to: Birgit Schittek, email: birgit.schittek@uni-tuebingen.de Keywords: melanoma, MAPK inhibition, therapy resistance, p90 ribosomal S6 kinase, YB-1 Received: January 18, 2017 Accepted: March 06, 2017 Published: March 15, 2017 ABSTRACT The clinical availability of small molecule inhibitors specifically targeting mutated BRAF marked a significant breakthrough in melanoma therapy. Despite a dramatic anti-tumour activity and improved patient survival, rapidly emerging resistance, however, greatly limits the clinical benefit. The majority of the already described resistance mechanisms involve a reactivation of the MAPK signalling pathway. The p90 ribosomal S6 kinase (RSK), a downstream effector of the MAPK signalling cascade, has been reported to enhance survival of melanoma cells in response to chemotherapy. Here, we can show that RSK activity is significantly increased in human melanoma cells with acquired resistance to the BRAF V600E/K inhibitor vemurafenib. Interestingly, inhibition of RSK signalling markedly impairs the viability of vemurafenib resistant melanoma cells and is effective both in two-dimensional and in three-dimensional culture systems, especially in a chronic, long-term application. The effect of RSK inhibition can be partly replicated by downregulation of the well-known RSK target, Y-box binding protein 1 (YB-1). Intriguingly, RSK inhibition also retains its efficacy in melanoma cells with combined resistance to vemurafenib and the MEK inhibitor trametinib. These data suggest that active RSK signalling might be an attractive novel therapeutic target in melanoma with acquired resistance to MAPK pathway inhibitors.
47
Mutations of the BRAF gene in human cancer
Helen Davies, Graham R. Bignell, Charles Cox et al. · Nature · 2002 · 10.7K citations
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem, Neville E. Sanjana, Ella Hartenian et al. · Science · 2013 · 5.5K citations · Full text